Published 2012 Articles:
1. شيرين ز, نسرين گ, منصور ب, زهره ص. بررسي رابطه ابعاد شخصيت و ابتلا به سرطان بر اساس پرسشنامه سرشت و منش کلونينجر (TCI).
2. Lashkar JM, Amjadi M, Soleymani J, Tamizi E, Panahi-Azar V, Jouyban A. Development and validation of a terbium-sensitized LuminescenceAnalytical method for Deferiprone. Iranian journal of pharmaceutical research: IJPR. 2012;11(3):771.
3. Ziaei JE, Pourzand A, Bayat A, Vaez J. Patterns of metastasis and survival in breast cancer patients: a preliminary study in an Iranian population. Asian pacific journal of cancer prevention. 2012;13(3):937-40.
4. سيدهادي چ, جمال عض, اكبر مپع, رويا د. الگوي ايمونوفنوتايپينگ لوسمي لنفوسيتي حاد بزرگسالان و ارتباط آن با پاسخ اوليه يا القايي.
5. Valizadeh L, Zamanzadeh V, Rahmani A, Howard F, Nikanfar AR, Ferguson C. Cancer disclosure: Experiences of Iranian cancer patients. Nursing & health sciences. 2012;14(2):250-6.
6. Manzoori JL, Amjadi M, Soleymani J, Tamizi E, Rezamand A, Jouyban A. Determination of deferiprone in urine and serum using a terbium‐sensitized luminescence method. Luminescence. 2012;27(4):268-73.
7. Aghahosseini SS, Rahmani A, Abdollahzadeh F, Kermani IA. The relation between awareness of cancer diagnosis and spiritual health among cancer patients. Journal of caring sciences. 2012;1(2):67.
8. Abdollahzadeh F, Aghahossini SS, Rahmani A, Kermani IA. Quality of life in cancer patients and its related factors. Journal of caring sciences. 2012;1(2):109.
9. Nojavan M, Shamsasenjan K, Movassaghpour AA, Akbarzadehlaleh P, Torabi SE, Ghojazadeh M. Allelic prevalence of ABO blood group genes in Iranian Azari population. BioImpacts: BI. 2012;2(4):207.
10. Esfahani A, Ghoreishi Z, Nikanfar A, Sanaat Z, Ghorbanihaghjo A. Influence of chemotherapy on the lipid peroxidation and antioxidant status in patients with acute myeloid leukemia. Acta Medica Iranica. 2012:454-8.
11. Ghoreishi Z, Esfahani A, Djazayeri A, Djalali M, Golestan B, Ayromlou H, et al. Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial. BMC cancer. 2012;12(1):1-8.
12. Hagh MF, Saki N, Khamisipour G. Hypermethylation Status of Promoter is an Epigenetic Change in Lymphoied Malignancies. International Journal of Hematology-Oncology and Stem Cell Research. 2012:27-8.
13. Rahmani A, Mohammadian R, Ferguson C, Golizadeh L, Zirak M, Chavoshi H. Posttraumatic growth in Iranian cancer patients. Indian journal of cancer. 2012;49(3):287.
14. Mashayekhi S, Sattari MR, Maleki-Dizaji N, Asadi M, Islamboulchilar M, Parvizpour A, et al. Pharmacy students' self-identified interests in a hospital pharmacy internship course in Iran. Research and Development in Medical Education. 2012;1(2):49-53.
15. Seifi S, Kermani IA, Dolatkhah R, Kermani AA, Sakhinia E, Asgarzadeh M, et al. Prevalence of oral human papilloma virus in healthy individuals in East azerbaijan province of iran. Iranian journal of public health. 2013;42(1):79.
16. Dolatkhah R, Bazavar MR, Poureisa M, Kermani IA, Gharamaleki JV, Sanaat Z, et al. Successful management of total knee replacement in a high responder hemophilia patient with a history of inhibitor. Iranian Red Crescent Medical Journal. 2013;15(1):18.
17. Hallaj-Nezhadi S, Dass CR, Lotfipour F. Intraperitoneal delivery of nanoparticles for cancer gene therapy. Future oncology. 2013;9(1):59-68.
18. Shekoufeh B LA, Lotfipour F. Magnetic nanoparticles for antimicrobial drug delivery. Die Pharmazie-An International Journal of Pharmaceutical Sciences. 2012;67(10):817-21.
19. Nahaei M, Valizadeh H, Baradaran B, Nahaei M, Asgari D, Hallaj-Nezhadi S, et al. Preparation and characterization of chitosan/β-cyclodextrin nanoparticles containing plasmid DNA encoding interleukin-12. Drug research. 2013;63(01):7-12.
20. حق فد, نیا ن, مرتضوی, یوسف, سلیمانی, مسعود, et al. مقایسه بیان کمّی فاکتور نسخه‌برداری RUNX2 در تمایز سلول‌های بنیادی مزانشیمی با محیط تمایزی استئوبلاستی و داروی زولدرونیک اسید. مجله علمی دانشگاه علوم پزشکی رفسنجان. 2012;11(4):377-90.
21. Sattari M, Sheykhi D, Nikanfar A, Pourfeizi AH, Nazari M, Dolatkhah R, et al. The financial and social impact of thalassemia and its treatment in Iran. Pharmaceutical sciences. 2012;18(3):171-6.
22. Sattari M, Mashayekhi S, Mashayekhi S. Islam and addiction. Pharmaceutical sciences. 2019;18(3):151-8.
23. Sanaat Z, Tavangar S-M, Gharamaleki JV, Kermani IA, Ziae JE, Nikanfar A, et al. Cyclooxygenase-2 expression in lymphoma in north-west of iran. International journal of hematology-oncology and stem cell research. 2013;7(1):1.
24. Zamanzadeh V, Rahmani A, Valizadeh L, Ferguson C, Hassankhani H, Nikanfar AR, et al. The taboo of cancer: the experiences of cancer disclosure by Iranian patients, their family members and physicians. Psycho‐Oncology. 2013;22(2):396-402.
25. Ziaei JE, Sanaat Z, Asvadi I, Dastgiri S, Pourzand A, Vaez J. Survival analysis of breast cancer patients in northwest Iran. Asian Pacific Journal of Cancer Prevention. 2013;14(1):39-42.
26. Sattari M, Sheykhi D, Nikanfar A, Pourfeizi AH, Nazari M, Dolatkhah R, et al. The adverse effects of thalassemia treatments including blood transfusion and main pharmacological therapies. Pharmaceutical Sciences. 2013;18(4):199-204.
27. Nowrouz P, Taghipour H, Dastgiri S, Bafandeh Y, Hashemimajd K. Nitrate determination of vegetables in Varzeghan City, North-western Iran. Health promotion perspectives. 2012;2(2):244.
28. Abdollahi S, Lotfipour F. PLGA-and PLA-based polymeric nanoparticles for antimicrobial drug delivery. Biomed Int. 2012;3(1):1-11.
29. Moosavi MA, Seyed Gogani N, Asvadi Kermani I. STUDY OF SURVIVIN AND IT’S NEW SPLICE VARIANT, SURVIVIN-2A, EXPRESSION IN CHRONIC MYELOID LEUKEMIA PATIENTS. Studies in Medical Sciences. 2013;23(7):776-83.